Stem cell-derived liver cells for drug testing and disease modeling

Area of Science:

• Stem cell biology
• Hepatology
• Biotechnology

Background:

• Primary human hepatocytes (PHHs) are limited for in vitro liver models due to donor organ shortages.
• Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide a renewable source for generating hepatocyte-like cells.
• iPSCs enable patient-specific disease modeling and genotype-phenotype studies.

Purpose of the Study:

• To review culture platforms for hESC-HHs and iPSC-HHs.
• To discuss microfabrication for enhancing liver cell function.
• To highlight future directions for stem cell-derived liver models.

Main Methods:

• Overview of existing hESC-HH and iPSC-HH culture platforms.
• Discussion of semiconductor-driven microfabrication for cell microenvironment control.
• Analysis of current limitations and future improvements in stem cell differentiation protocols.

Main Results:

• hESC-HHs and iPSC-HHs show utility in drug development and modeling liver diseases (e.g., A1AT deficiency, viral hepatitis, malaria).
• Microfabrication tools can improve in vitro liver function.
• Current differentiation protocols require further optimization for adult liver similarity.

Conclusions:

• Stem cell-derived hepatocytes offer a sustainable alternative to PHHs for research and therapy.
• Enhanced in vitro liver models are crucial for advancing drug discovery and personalized medicine.
• Future research should focus on refining differentiation and culture systems for next-generation liver models.